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j ourna l homepage: www.eb iomed ic ine.comEditorialNew Indications and a Sense of (Re)purposeWhat do metformin, Viagra and Avastin have in common? They are
all used to treat conditions besides those theywere originally developed
to treat. Drug repositioning, or repurposing, describes the process of
deploying therapeutics to new indications. The impetus to ﬁnd addi-
tional applications for currently prescribed drugs, as well as novel uses
for shelved compounds, is becoming increasingly important as the
drug development pipeline dwindles.
The crux of the problem is money. It typically takes over a decade
and in excess of a billion dollars to bring a drug to market. This
imposes severe ﬁnancial pressure on the R&D departments of phar-
maceutical companies and non-commercial entities embarking on
drug development. Failures that occur later on in the development
process are particularly expensive. The magnitude of the problem
is difﬁcult to ascertain, but a conservative estimate is that b10% of
mature preclinical de novo compounds make it to product launch.
This attrition means that the majority of unsuccessful compounds
are dropped or stalled, never to be heard of again. Not only is this a
costly and inefﬁcient process, but important data concerning drug
safety proﬁles and synthesis are never published, creating a black
hole for valuable information.
While the notion of drug repositioning is not new, the drive to rescue
compounds from the brink of obscurity has gained momentum as a
means to stimulate the currently ﬂawed drug development model.
There are two forms of repositioning: drug-centered, whereby promis-
cuous drugs act on more than one biological target (such as metformin
which activates AMPK in diabetes and a variety of molecular targets in
cancer); and disease-centered, in which diseases that share pathophys-
iological mechanisms can be affected by the same drug (such as Viagra,
which is used to treat erectile dysfunction and pulmonary arterial hy-
pertension by causing vasodilation via a reduction in cyclic guanosine
monophosphate degradation).
From a business standpoint, repositioning makes sense as a great
deal of information about the pharmacokinetics, toxicity and manufac-
ture of a drug is already known. This knowledge can offer an advantage
over de novo drugs that have yet to pass these scientiﬁc and regulatory
barriers, translating to a shorter time to market and improved success
rate. However, there is an argument that resurrecting failed and
abandoned compounds might have a negative impact on scientiﬁc
innovation and the pursuit of novel drugs. This is true to some extent,
but drugs can act in unexpected ways in new indications, enabling
a deeper understanding of a disease that can stimulate new avenues
of research. This was recently exempliﬁed by the use of glitazones to
treat chronic myeloid leukemia (CML) as reported in Nature on
September 2, 2015. These peroxisome proliferator-activated receptor-γ
agonists are traditionally used to treat diabetes, but Prost and
colleagues found that they were also able to target the CML leukemiahttp://dx.doi.org/10.1016/j.ebiom.2015.10.003
2352-3964/© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NCstem cell pool, achieving a complete molecular response in all CML
patients tested.
Drug repurposing also provides the opportunity to foster collabora-
tion between industry and academia. This relationship is mutually ben-
eﬁcial: academic researchers are allowed access to well-characterized,
clinical-relevant compounds to test in new indications, and the in-
dustrial partner potentially gains knowledge of new molecular targets,
and the etiology and pathophysiology of disease. At the recent 28th
European College of Neuropsychopharmacology (ECNP) Congress in
Amsterdam, The Netherlands, David Nutt gave a passionate talk about
the Medicines Chest, an initiative whereby the ECNP acts as broker be-
tween researchers and industry to provide pharmacological com-
pounds for human experimental medicine studies. So far, 23
pharmaceutical companies are on-board with N30 compounds in the
chest.
This enterprise has been mirrored by similar efforts worldwide to
unite stakeholders committed to drug-repurposing. The UKMedical Re-
search Council oversees the Industry Asset Sharing Initiative in which
seven industry partners offer deprioritized molecules to research scien-
tists. A recent success was AZD3355, a GABA-B receptor agonist, origi-
nally used to treat gastro-esophageal reﬂux and repurposed to treat
chronic cough. In the United States, the National Center for Advancing
Translational Sciences (NCATS) also has a Repurposing Drugs Program
that is divided into early-stage repurposing (high-throughput screens
of already approved compounds), and late-stage repurposing (regulato-
ry–quality data packages to support a drug's entry into clinical trials for
new disease indication). A recent achievement came from a partnership
between NCATS-associated academic scientists and AstraZeneca
through the repurposing of saracatinib. Originally developed to treat
cancer, saracatinib was recently shown to restore brain function in
mouse models of Alzheimer's disease and entered a Phase 2a clinical
trial within 18 months — a process that would take up to a decade
using an untested compound.
Despite these successes, repurposing drugs can be a controversial
business. Pharmaceutical companies can remove a perfectly active
drug from one indication, reformulate it in a minor way without any
chemical alteration (for example modifying the dose or altering the
formulation), and rebrand it for a new indication at a substantially
higher price. Limiting the availability of the anti-cancer drug Avastin
(bevacizumab) for wet age-related macular degeneration (AMD) is
a well-reported example, as it has comparable efﬁcacy (according
to NIH's comparison of AMD treatments trials), and is far less costly
than the prescribed alternative Lucentis (ranibizumab). While
some claim that off-label use of bevacizumab to treat wet AMD is
unsafe, many doctors feel this is a cynical pharmaceutical maneuver
that prioritizes proﬁt ahead of patients. This debate is ongoing and-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1258 Editorialbevacizumab is not, at present, approved by the US Food and Drug
Administration or European Medicine Agency as a treatment for wet
AMD.
Finding new uses for existing compoundsmakes ﬁnancial and scien-
tiﬁc sense even though its implementation can be challenging. It isworth remembering that a unifying need to improve disease treatment
should prevail and that sometimes, contrary to the old adage, you can
teach an old dog new tricks.
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